In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 111 to 120 of 303

TitleTypeExpected publication date
Fruquintinib for previously treated metastatic colorectal cancer ID6274Technology appraisal guidance
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]Technology appraisal guidanceTBC
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]Technology appraisal guidance
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]Technology appraisal guidanceTBC
Glaucoma - lerdelimumab (CAT-152) [ID383]Technology appraisal guidanceTBC
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202]Technology appraisal guidanceTBC
Guselkumab for previously treated moderately to severely active Crohn's disease ID6238Technology appraisal guidanceTBC
Guselkumab for treating moderately to severely active ulcerative colitis ID6237Technology appraisal guidanceTBC
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]Technology appraisal guidanceTBC
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All